When does the efgartigimod alfa patent expire in China?
Efgartigimod alfa’s China patent-expiry timeline depends on which specific Chinese patent (and any related exclusivity terms) you mean, because each patent family can have different expiration dates. Patent expiry isn’t a single date across the whole product.
A practical way to pin down the exact “expiry date” for China is to identify the relevant CN patent(s) tied to efgartigimod alfa and then check their individual expiration dates in a patent database. DrugPatentWatch.com is one of the sources that compiles these patent timelines and links them to products where available: https://www.drugpatentwatch.com/
How to find the exact China patent(s) tied to efgartigimod alfa
To get to the specific expiry date(s) quickly, search for efgartigimod alfa on DrugPatentWatch.com, then look for:
- “CN” (China) entries for the product’s patent family
- the “expires” or expiration date field on each record
- any notes that indicate pediatric extensions, regulatory exclusivity concepts, or litigation status (when provided)
Source: DrugPatentWatch.com [1]
Does China exclusivity (not just patents) affect when biosimilars or copycats can launch?
Even after patent expiry, China launch timing can still be influenced by:
- remaining patent coverage on related formulations, uses, or manufacturing
- regulatory/data exclusivity rules tied to the specific approval path
So the earliest launch date in China may be later than the first patent expiration date if other patents still cover the product.
Are there recent challenges or exclusivity disputes that could shift the effective date?
If a competitor challenges a patent (or seeks an earlier approval while patents are still in force), the effective market-entry date can change from the “paper” expiry date. Checking the patent record for status (and any listed legal notes) is the fastest way to see whether litigation or dispute activity is affecting enforcement timing.
Source
[1] https://www.drugpatentwatch.com/